Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blue dye could ease pain after hemorrhoid surgery

NCT ID NCT07164807

Symptom relief Sponsor: The Affiliated Hospital of Putian University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding methylene blue to a standard painkiller can reduce pain after hemorrhoid surgery. About 177 adults with severe hemorrhoids will receive one of two doses of methylene blue plus ropivacaine. Researchers will track pain scores, painkiller use, and quality of life for one month after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylene blue combined with ropivacaine
What this could lead to
If it works, this could provide a better way to manage pain after hemorrhoid surgery, reducing the need for strong painkillers.
What could go wrong
This is a small, early-phase trial with only 177 people. The results may not apply to everyone, and there is a risk of side effects like skin irritation or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 177 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged between 18 and 75 years. 2. Diagnosed with Grade III-IV hemorrhoids according to the Goligher classification. 3. Scheduled to undergo standard Milligan-Morgan hemorrhoidectomy. 4. Procedure performed under spinal anesthesia alone. Exclusion Criteria: 1. Pregnancy or lactation. 2. Current immunotherapy or coagulopathies. 3. Contraindications to any protocol-specified agents (e.g., history of severe allergic reactions to methylene blue or ropivacaine). 4. Concurrent anorectal pathologies (e.g., perianal abscess, anal fistula, fecal incontinence). 5. Comorbid systemic conditions (e.g., cardiac/hepatic/renal insufficiency, diabetes mellitus, coagulopathy, peptic ulcer disease). 6. Incomplete perioperative documentation. 7. Inability to comply with follow-up protocols.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methylene blue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemorrhoid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methylene blue Milligan-morgan hemorrhoidectomy Mixed hemorrhoids

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Putian University

    Putian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.